• The Park

    The Park

    Our values
    Testimonials
    Getting here
    2040 Vision

    See our plans to become a pioneering research and innovation district

    Learn More
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn More
  • Find a workspace
    R&D workspace

    Research and development workspaces for innovation and manufacturing

    Industrial space

    High-tech industrial units now available in Oxfordshire

    Lab space

    Fitted or unfitted laboratory space in Oxfordshire

    Co-working office space at Bee House

    Welcome to Oxfordshire’s largest and buzziest co-working space

    Serviced office space

    Flexible office space for agile businesses in Oxfordshire

    Office space

    Readily available office spaces for companies of all sizes

    Amenity space

    Food & beverage, retail and leisure spaces, including the new Signal Yard development.

    Meeting and conference space

    Available for both Milton Park occupiers and off-park companies to hire.

    Design and build

    Looking for landmark laboratory, flagship head office or bespoke R&D workspace? We can help…

    Learn more
    Future developments

    Discover future developments at Milton Park including Nebula and Signal Yard

    Learn more
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more
  • Community
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more

    Community

    Amenities
    Who's here
    Find a job
    Meeting and Conference Space

    Available for both Milton Park occupiers and off-park companies to hire

    Learn more
  • News
  • Events
  • About us
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn more

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
  • The Park
    back

    The Park

    The Park

    The Park

    back

    The Park

    Our values
    Testimonials
    Getting here

    2040 Vision

    Getting here

  • Find a workspace
    back

    Find a workspace

    Find a workspace

    Search by type

    back

    Search by type

    R&D workspace
    Industrial space
    Lab space
    Co-working office space at Bee House
    Serviced office space
    Office space
    Amenity space
    Meeting and conference space

    Design and build

    Future developments

    Signal Yard

  • Community
    back

    Community

    Community

    Community

    back

    Community

    Amenities
    Who's here
    Find a job

    Meeting and Conference Space

  • News
    back

    News

    News

  • Events
    back

    Events

    Events

  • About us
    back

    About us

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
    back

    Contact

    Contact

HomeCommunity

News  /  Community

Company Spotlight: Emergex Vaccines

Published on 18 January 2022

Back to results

We recently caught up with Emergex Vaccines, eager to learn more about the company’s work developing a special kind of vaccine which could reduce regular booster jabs in the fight against Covid-19. The team are currently in clinical trials using microneedles to deliver the vaccines – as well as developing microneedle-based skin patches which will make administration of the vaccine much easier for patients and healthcare professionals.
Background
Founded in 2016, Emergex’s Research and Development (R&D) operation is based out of Milton Park. A clinical stage biotechnology company developing novel T-Cell priming vaccines, Emergex works to tackle some of the most serious health concerns facing the global population. From Dengue Fever, to Zika, Ebola, pandemic influenza and more recently Covid-19, Emergex offers an alternative to antibody-focused vaccines, which require frequent booster jabs.

T-Cells have been described as the ‘heavy armour’ of the immune system, playing a huge role in the immune response of the body. Current Covid vaccines are designed to elicit an antibody-based response, however by specifically targeting T-cells, this could potentially offer much longer (up to decades!) protection from disease.

What do Emergex do?
Emergex’s vaccine technology is designed to mimic the course of natural infection, providing a broad and robust immune response. Emergex’s work involves developing these vaccines to be given to patients through microneedles which deliver the vaccines to the top layer of skin. The vaccines are fully synthetic, allowing them to be stable at room temperature and easily transported across the globe to the patients who need it most.

Robin Cohen, Chief Commercial Officer at Emergex Vaccines, explains further: “Our T-Cell priming vaccines may offer significant benefits over current Covid-19 vaccines – including longer lasting immunity and broader protection against new variants and mutations. With the government’s current efforts in encouraging booster vaccine uptake with the Omicron variant, technology like ours could potentially see the need for regular boosters become redundant.”

Exciting times
This year has been incredibly exciting for the team, with a great deal of clinical investment and the first human clinical trials in Switzerland are underway.
The trial has two arms – one addressing Dengue Fever, which is currently in the follow-up stages, and another focusing on Covid-19 which will take place this month. The vaccine and microneedles being tested in the trials are likely to be used in a skin patch which is currently in development.
Robin added: “We’re delighted to see these trials take place and are excited for the upcoming data which will help to support the development of our vaccines for both Covid-19 and Dengue Fever – helping to address the most current healthcare crisis as well as bringing the potential for robust and long-lasting immune protection to some of the world’s most impacting diseases.

Why Milton Park?
Robin added: “With our R&D facility being based at Milton Park, we benefit from state-of the-art, modern facilities within a hub of life science innovation. We’re very proud to be part of this biotechnology cluster, surrounded by likeminded companies in a welcoming environment.”

Philip Campbell, Commercial Director at Milton Park, said: “As a science and technology community, we’re committed to growing and providing a hub for our businesses to innovate and collaborate – it’s a real honour to have Emergex’s inspiring work in vaccine technology take place here with us.”

To learn more about Emergex and the company’s latest news, visit the website: https://emergexvaccines.com/

Share this article

Related news

News
News / Business

Nearly full: Bee House is the place to 'bee'

Published on 28 April 2025
News / Occupier News

Innovation community news – April

Published on 25 April 2025
News / Business

Company Spotlight: TreQ

Published on 25 April 2025

Sign up to our newsletter

Subscribe

Subscribe to the Milton Wonder newsletter for latest news, events and competitions.

"*" indicates required fields

What best describes your relationship with Milton Park?*
Please select all that apply
Consent*

We’re here to help
Call us on +44 (0)1235 865 555

Or follow
us on
  • Privacy Policy
  • Cookie Preferences

®Milton Park is a registered trademark, owned by MEPC Milton GP Limited, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire OX14 4SB

Registered Office: MEPC Milton GP Ltd, Sixth Floor, 150 Cheapside, London EC2V 6ET

Registered in England, No. 7669538 | ® Copyright MEPC Milton GP Ltd 2023